Who are Allogenic Human Islet Cells's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, Cord Blood Cell, Leukocyte rich platelet rich plasma, PCRA (Intermittent injection), IL-7/IL-15 pre-treated CD19 cells, Allogenix Plus.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/allogenic-human-islet-cells.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Allogenic Human Islet Cells — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogenic Human Islet Cells (Allogenic Human Islet Cells) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Diabetes.

phase 2 Cell therapy Diabetes Biologic Live · refreshed every 30 min

Target snapshot

Allogenic Human Islet Cells (Allogenic Human Islet Cells) — City of Hope Medical Center. Allogeneic human islet cells restore insulin-producing capacity by replacing or supplementing the patient's own dysfunctional beta cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Allogenic Human Islet Cells TARGET	Allogenic Human Islet Cells	City of Hope Medical Center	phase 2	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Cord Blood Cell	Cord Blood Cell	China Spinal Cord Injury Network	marketed	Cell therapy
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
PCRA (Intermittent injection)	PCRA (Intermittent injection)	Örebro University, Sweden	marketed	Cancer vaccine / Autologous cell therapy
IL-7/IL-15 pre-treated CD19 cells	IL-7/IL-15 pre-treated CD19 cells	jiangjingting	marketed	CAR-T cell therapy	CD19
Allogenix Plus	Allogenix Plus	University of Missouri-Columbia	marketed	Allogeneic cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Allogenic Human Islet Cells — Competitive Intelligence Brief. https://druglandscape.com/ci/allogenic-human-islet-cells. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab